<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01854294</url>
  </required_header>
  <id_info>
    <org_study_id>GALS 001</org_study_id>
    <nct_id>NCT01854294</nct_id>
  </id_info>
  <brief_title>GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)</brief_title>
  <acronym>GALS</acronym>
  <official_title>GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genervon Biopharmaceuticals, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Genervon Biopharmaceuticals, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GM604 is an endogenous human embryonic stage neural regulatory and signaling peptide that
      controls the development, monitoring and correction of the human nervous system. Neurological
      diseases are multisystem, multifactorial, and single target drugs are ineffective. Genervon's
      Master Regulators play a significant role in embryonic/fetal nervous system development and
      are potent disease modification drug candidates modulating many pathways including
      inflammation, apoptotic, and hypoxia. The study drug is an regulatory peptide with a sequence
      identical to one of the active sites of human Motoneuronotrophic Factor and is manufactured
      by solid phase synthesis. Pre-clinical research indicates it to be a neuro-protective agent
      in animal models of ALS, motorneuron diseases, PD, other neuro-degenerative diseases and
      stroke. GM604 controls and modulates over many known and significant ALS genes with positive
      effects interactively and dynamically through multiple pathways, and up to twenty-two
      biological processes, including neuro-protection, neurogenesis, neural development, neuronal
      signaling, neural transport, and other processes. GM6 is not a cocktail of drugs, but one
      master regulator peptide drug that functions through multiple pathways. Genervon hypothesized
      that studying the biomarkers of protein expressions of these ALS genes such as SOD1 and the
      protein expression of substances such as tau, NF-H, Cystatin C which were indications of
      degeneration of neuron in the CSF collected from ALS patients will provide information of the
      possible GM604's mechanisms of action in treating ALS. 1. This pilot trial is designed to
      test proof of principle, i.e. determine if a 2-week IV bolus treatment with this agent can
      (1) change ALS protein expression (target biomarkers and efficacy biomarkers) after treatment
      (2) have preliminary effects measures of ALS disease clinical progression.

      Study Objectives are:

        1. To test the safety and tolerability of GM604 in a population of ALS patients.

        2. To test for changes in ALS biomarkers before and after treatment.

        3. To determine preliminary effects of injections of GM604 on measures of ALS disease
           biomarkers and clinical progression
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background

        1. In the early 1990s Genervon hypothesized that CNS/PNS and rare motoneuron diseases and
           disorders involve the interplay of a highly complex, multifactorial process of many
           non-dominant effectors in an interactive dynamic network. Therefore Genervon decided for
           its drug development strategy the classic single target drug development paradigm is not
           likely leading to a cure.

        2. Genervon also hypothesized that aging is likely the initial multifactorial triggers that
           lead to multiple defective or degraded gene products accumulating with advancing years.
           However the key to a cure for many human neurological disorders is in the subsequent
           common terminal cascade coinciding with the onset of neurological deficits. The terminal
           cascade involves the shared pathways of interactive multifactorial pathogenic mechanisms
           that lead to the ultimate demise of neurons. Therefore Genervon's strategy is not to
           find the triggers or the residue debris of neuron death in discrete areas of the central
           nervous system.

        3. Genervon recognized the limited human capacity to design a drug that can dynamically and
           interactively modulate multiple pathways and genes. Therefore one possible drug
           development strategy is to find the endogenous early stage regulatory molecule(s) that
           controls the development, monitoring and correction of the human nervous system.

        4. Genervon developed a novel proprietary technology platform named Protein Bands Selection
           by Function to find the fetal signal regulators. One of the discoveries is a 33 amino
           acid peptide we named human Motoneuronotrophic Factor (MNTF), its gene sequence and its
           chromosome location.

        5. Genervon developed another novel platform named In Silico Analysis to find active sites
           within bigger proteins. Within the MNTF peptide, Genervon identified a family of nine
           embryonic stage human multifactorial master regulators which govern nervous system
           development, protection and correction. These master regulators are highly expressed in
           week 9 of embryonic/fetal development, a time of incredible intricacies, but truly
           remarkable consistency as well.

        6. Genervon has developed one of the nine master regulators named GM6 for disease
           modification of CNS/PNS and neurodegenerative diseases and disorders with shared or
           common pathways of interactive multifactorial pathogenic mechanisms. GM6 binds to
           Insulin Receptor beta sub-unit and IGF1R/IGF2R which also have the identical sub-unit.
           GM6 penetrates the Blood Brain Barrier (BBB) and activates many appropriate genes
           through multiple pathways to induce anti-inflammatory, anti-apoptotic, anti-oxidative
           and regenerative effects in response to the dynamic distress signals from the nervous
           system.

        7. GM6 is also known as GM604, GM602 and GM608. Drug name GM604 is assigned to ALS
           indication. GM602 is assigned to stroke indication. GM608 is assigned to Parkinson
           Disease indication.

        8. The investigational drug GM604 is a regulatory/signaling peptide with a sequence
           identical to one of the nine active sites of human Motoneuronotrophic factor (MNTF),
           also referred to as GM6 in studies. MNTF is a novel human endogenous developmental stage
           neurotrophin for the nervous system with a specific human chromosome location.

        9. Pre-clinical efficacy studies: The investigators' preclinical animal study has shown
           that intravenously injected GM604 is able to penetrate the blood-brain barrier and enter
           the brain. GM604 has shown neuroprotection in a variety of in vitro and animal models of
           numerous CNS diseases including ALS, ischemic stroke, spinal cord injuries, Parkinson's
           disease (PD), MS, Alzheimer and Huntington Disease.

       10. GM6 provided neuroprotection for neurons in vitro against soluble inflammatory factors
           in human CSF from patients with various CNS diseases. It increased neurons survival by
           175% after exposure to ALS patients' CSF, by 191% in AD patients' CSF, by 198% in PD
           patients' CSF, by 205% in Stroke patients' CSF, by 246% in MS patients' CSF and by 273%
           in HD patients' CSF.

       11. Preclinical research in animal models indicates GM604 to be a neuroprotective agent in
           animal models of ALS, motoneuron disease, Parkinson's disease and stroke. In ALS model,
           SOD1 mice from Jackson Lab stock #G93A were treated with GM604 at 0, 1 and 5 mg/kg. SOD1
           mice were examined for age of disease onset, age of death, and behavioral expression of
           the disease (CS=Clinical score). GM604 prolonged life span in ALS mice SOD1 by 30%
           [(163.5-126)/126 = 30%], delayed median clinical score by 53%, delayed symptoms onset by
           27% [(145.5-114.5)/114.5 = 27%] at 5 mg/kg dose. The conclusion is that GM6
           significantly showed a dose dependent effect in delaying age of onset of the disease,
           age of death, increasing grip strength and rota-rod performance, and improving clinical
           score of the treated animals.

       12. The investigators found out later in the study of Wobbler Mouse model that the optimal
           dose for SOD1 mice model should probably be 20 mg/kg and will probably see even more
           significant effects if 20 mg/kg were used in the SOD1 mice study.

       13. GM604 20mg/kg dramatically increased the survival life span by 500% (6 fold from 7-14
           weeks to 55-65 weeks) and the control animals and animals treated with low doses of GM6
           showed a continual decrease in grip strength. Wobbler mice treated with GM6 at 10-20
           mg/kg showed an improvement in grip strength out to 4 weeks (3 fold). GM604 10 and 20
           mg/kg treatment showed a significant increase in body weight out to 8 weeks following
           treatment.GM604 10 and 20 mg/kg treatment increased of preservation of motor neurons by
           160% (2.6 fold).

      The conclusion is that GM604 was found to be efficacious in an in vivo mouse model of
      neurological disease. The effectiveness of GM604 was dose-dependent and indicates that GM604
      may be beneficial in treating various neurological disorders.

      Rationales

        1. This pilot trial is designed to test proof of principle, i.e. determine if a 2-week IV
           bolus treatment with this agent can (1) change ALS protein expression (target biomarkers
           and efficacy biomarkers) after treatment (2) have preliminary effects measures of ALS
           disease clinical progression.

        2. Previous human experience: A Phase 1 Clinical Trial Study has been completed. The Phase
           1 Trial primary objective is to determine the safety and tolerability and to establish
           the pharmacokinetic and pharmacodynamic properties of GM602 at 0.5, 1.5, and 5.0 mg/kg
           administered as a single bolus intravenous dose in human subjects and after 3
           consecutive daily doses of GM602 at the highest safe and tolerated dose of 5.0 mg/kg.
           The Phase 1 study established that 3 consecutive daily doses of 5.0 mg/kg of GM602 are
           safe and tolerated.

        3. Concurrently, other IND and on-going clinical trials with GM6 are:

      IND 77,789: &quot;A Phase 2 double blinded, randomized, placebo controlled dose escalation Study
      to Evaluate the Efficacy and the Safety of GM602 in Patients with Acute Middle Cerebral
      Artery Ischemic Stroke within an 18 h-hour treatment window. Acronym/Title is GMAIS. GM602
      received fast track designation for ischemic stroke in 2007. The stroke trial has not
      completed enrollment and has not unblinded the treatment randomization to generate drug
      related safety report.

      IND 109,441: &quot;GM602 in A Phase IIA Pilot double-blinded, randomized, placebo controlled trial
      in mild to moderate Parkinson Disease (PD). Acronym/Title is GAP-PD. The PD trial is
      recruiting patients.

      Possible GM604 MOA in ALS

        1. More and more scientists are publishing papers advocating that ALS is a multifactorial
           disease. Other rare diseases including CNS/PNS diseases and disorders are multifactorial
           and multisystem diseases as well, i.e. multiple interactive biologic systems and genes
           are compromised and failing like domino.

        2. One of the major reasons for CNS clinical trials that have uniformly failed is that the
           classic drug development paradigm of designing single target drug for CNS/PNS and rare
           diseases' pathogenesis simply would not be able to handle the multifactorial nature of
           the complex diseases.

        3. An initial trigger(s) which is likely to be multifactorial and cumulative is followed by
           a terminal cascade which also involves interactive multifactorial pathogenic mechanisms,
           coinciding with the onset of neurological deficits, genes mutation and or expression of
           misfolded proteins. That is simply why a single target drug is not able to do the job.
           Most neurological diseases and disorders have common underlying pathogenic mechanisms
           that lead to neural death. Our drug development strategy is to find an endogenous
           regulator to interactively and dynamically modulate these common underlying pathogenic
           mechanisms.

        4. Genervon changed the drug development paradigm from hitting a single gene/pathway to a
           comprehensive and dynamic, multifactorial approach to treat complex rare and
           neurodegenerative diseases with a multi-factorial drug GM604. GM604 is one of the
           embryonic/fetal stage MNTF master regulators that is an endogenous signaling peptide for
           the development and regulations of the nervous system development. GM604 is
           multifactorial and corrects inadvertent errors in embryonic/fetal development and this
           neuroprotection and correction property may be applied to neurodegenerative disease
           therapy in adults.

        5. Genervon studied the mechanisms of action of GM6 by DNA microarray technique. GM604
           controls and modulates many known and significant ALS genes with positive effects,
           through multiple pathways interactively, systemically and dynamically. Our master
           regulator peptide drug modulates not just one but many ALS related genes. It is not a
           cocktail of drugs, but one master regulator peptide drug.

        6. Mechanisms that have been postulated in ALS are a complex interplay between multiple
           pathogenic processes including oxidative stress, protein aggregation, mitochondrial
           dysfunction excitotoxicity, and impaired axonal transport. GM604 modulates genes
           involved in these pathways and others. Genervon has also identified some genes to be
           tested as targets.

        7. ALS is notoriously fatal and has many alternate forms with different pathogenesis.
           Therefore all the previous single target drug trials have to restrict the enrollment to
           very small selective segment of ALS patients. With the potential that GM604 functions
           through multiple pathways and modulate multiple ALS related genes, Genervon believes
           GM604 can potentially treat ALS patients from a variety of segments instead of
           restricting to small selective segment of ALS patients. Genervon is proposing an ALS
           Phase 2 clinical trial that is broadly inclusive.

      Use of Biomarkers for ALS

      Most late-phase clinical trials across all diseases fail to demonstrate drug efficacy between
      case and controls. The incorporation of biomarkers within clinical trials may reduce this
      'drug attrition' rate. The biomarkers to be incorporated into clinical trials can be
      subdivided into:

        1. 'Target' biomarkers (the drug hits its target and, therefore, provide benefit),

        2. 'Efficacy' biomarkers (indicators of positive drug effect (result) via the mechanism of
           drug action).

        3. 'Efficacy/Target biomarkers.

      Genervon hypothesized that modulating disease causing genes may modulate ALS disease
      progression.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy by percent change in biomarker in th CSF at week 12 from baseline</measure>
    <time_frame>baseline, week 2, week 12</time_frame>
    <description>Efficacy by percent change in biomarker in the CSF at week 12 from baseline: (a) Efficacy biomarkers (b) Target biomarkers (c) Efficacy/target biomarkers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>baseline, week 2, week 12</time_frame>
    <description>Safety: 1. adverse event frequency and severity, changes in vital signs, clinical laboratory values. 2. Serious adverse event frequency</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability</measure>
    <time_frame>Baseline, week 2, week 12</time_frame>
    <description>Tolerability: The ability to complete the first 2 weeks of active treatment in the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy by percentage change of other biomarkers not as primary endpoint in the CSF at week 12 from baseline</measure>
    <time_frame>baseline, week 2, week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy by percentage change of biomarker in CSF at end of week 2 from baseline</measure>
    <time_frame>baseline, week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALSFRS-R</measure>
    <time_frame>Symptom onset, screening, baseline, week 2, week 6, week 12</time_frame>
    <description>Progressive change in ALSFRS-R of each patient determined from the following data points:1) symptom onset, 2) baseline, 3) end of week 2 examination, 4) end of week 6 examination and 5) end of week 12 examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC)</measure>
    <time_frame>Symptom onset, baseline, week 2, week 6, week 12</time_frame>
    <description>Progressive change in Forced Vital Capacity (FVC) from the following data points: 1) symptom onset, 2) baseline, 3) end of week 2 examination, 4) end of week 6 examination and 5) end of week 12 examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Up and Go (TUG)</measure>
    <time_frame>Symptom onset, baseline, week 2, week 6, week 12</time_frame>
    <description>Progressive change in Forced Vital Capacity (FVC) from the following data points: 1) symptom onset, 2) baseline, 3) end of week 2 examination, 4) end of week 6 examination and 5) end of week 12 examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>muscle strength</measure>
    <time_frame>Symptom onset, baseline, week 2, week 6, week 12</time_frame>
    <description>Progressive muscle strength change measured by HHD (handheld dynamometry testing score) from the following data points: 1) symptom onset, 2) baseline, 3) end of week 2 examination, 4) end of week 6 examination and 5) end of week 12 examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker in blood</measure>
    <time_frame>baseline, week 2, week 6, week 12</time_frame>
    <description>Percentage changes in Biomarkers in blood between baseline and 1) the end of week 1, 2) end of week 2, 3) end of week 6 and 4) end of week 12. Comparing the changes encompassing the entire cohort of 10 subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>baseline, week 2, week 6, week 12</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>comparison of slopes (change in the rate of decline)of disease progression</measure>
    <time_frame>Symptom onset, baseline, week 2, week 6, week 12</time_frame>
    <description>Secondary analyses may consider a comparison of slopes (change in the rate of decline) for any hint of disease modification using placebo outcomes in patients matched for baseline features from a large database of recent clinical trials by NEALS showing stable rates of decline as historical controls.</description>
  </other_outcome>
  <other_outcome>
    <measure>stratification of patients by symptoms</measure>
    <time_frame>Symptom onset, baseline, week 2, week 6, week 12</time_frame>
    <description>Secondary analysis to allow a-priori stratification of patients by their symptoms if available
predominantly lower motor neuron
predominantly upper motor neuron
predominantly bulbar</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>GM604 treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 subjects will receive GM604. Each GM604 treated subject will receive a slow IV bolus injection (~1min) of 6.4 mL (320mg @50 mg/mL=6.4 mL) for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 subjects will receive placebo. 6.4 mL Bacteriostatic saline will be used for the Placebo group. Injections will be given to the subject in the same manner as in GM604 treated group. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GM604</intervention_name>
    <description>GM604 treated group subject will receive a slow IV bolus injection (~1min) of 6.4 mL (320mg @50 mg/mL=6.4 mL) for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).</description>
    <arm_group_label>GM604 treated</arm_group_label>
    <other_name>GM6</other_name>
    <other_name>GM602</other_name>
    <other_name>GM608</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo comparator</intervention_name>
    <description>Placebo comparator group subject will receive a slow IV bolus injection (~1min) of 6.4 mL bacteriostatic saline for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).</description>
    <arm_group_label>Placebo comparator</arm_group_label>
    <other_name>Bacteriostatic saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with ALS: Familial and Sporadic ALS, with symptom onset &lt; or equal to 24
             months.

          2. At least 18 years of age

          3. Subjects meet the El Escorial criteria of definite criteria for a diagnosis of ALS.

          4. Subjects can be on a stable dose of riluzole for at least a month or not taking or
             initiating riluzole for the duration of the trial.

          5. Not on any experimental medication for the last 1 month or five times the half-life of
             experimental medication.

          6. At screening, must have a Forced Vital Capacity (FVC) â‰¥ 65% of predicted capacity for
             age, height and gender.

          7. Have fully completed informed consent form

          8. Ability to comply with study procedures

          9. Women of child-bearing age must be on birth control. Pregnancy test should be done in
             women in child bearing age.

         10. Medically safe to have lumbar puncture to collect CSF

        Exclusion Criteria:

          1. History of liver disease, severe renal failure, diabetes, coronary heart disease,
             cancer

          2. Clinically significant EKG abnormality at screening

          3. Any comorbid condition which would make completion of the trial unlikely

          4. FVC &lt; 65%

          5. Presence of a bleeding disorder

          6. Allergy to local anesthetics

          7. Problem with CSF pressure

          8. Topical or other skin infection at the lumbar puncture site

          9. BMI &gt; 32 kg/m2

         10. Medical or surgical conditions in which a lumbar puncture is contraindicated

         11. Use of any anti-platelet or anticoagulant drugs, such as plavix, aggrenox, ticlid,
             warfarin or coumadin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroshi Mitsumoto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia Medical Center NY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Merit Cudkowicz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Medical Center NY</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2013</study_first_submitted>
  <study_first_submitted_qc>May 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2013</study_first_posted>
  <disposition_first_submitted>August 1, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>August 2, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 8, 2017</disposition_first_posted>
  <last_update_submitted>August 2, 2017</last_update_submitted>
  <last_update_submitted_qc>August 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALS</keyword>
  <keyword>motorneuron disease</keyword>
  <keyword>Central Nervous System (CNS) disease</keyword>
  <keyword>neurodegeneration</keyword>
  <keyword>neuroprotective</keyword>
  <keyword>mechanisms of action</keyword>
  <keyword>pathways</keyword>
  <keyword>biomarkers</keyword>
  <keyword>Cerebral Spinal Fluid (CSF)</keyword>
  <keyword>blood biomarkers</keyword>
  <keyword>multi-factorial</keyword>
  <keyword>multisystem</keyword>
  <keyword>single target</keyword>
  <keyword>pathogenic mechanisms</keyword>
  <keyword>Protein Bands Selection by Function</keyword>
  <keyword>in silico analysis</keyword>
  <keyword>active site</keyword>
  <keyword>protein</keyword>
  <keyword>peptide</keyword>
  <keyword>embryonic stage</keyword>
  <keyword>endogenous</keyword>
  <keyword>master regulators</keyword>
  <keyword>fetal development</keyword>
  <keyword>embryonic development</keyword>
  <keyword>common pathways</keyword>
  <keyword>Blood Brain Barrier (BBB)</keyword>
  <keyword>anti-inflammatory</keyword>
  <keyword>anti-apoptotic</keyword>
  <keyword>anti-oxidative</keyword>
  <keyword>regenerative</keyword>
  <keyword>distress signals</keyword>
  <keyword>neurotrophin</keyword>
  <keyword>Motoneuronotrophic factor (MNTF)</keyword>
  <keyword>ALS model</keyword>
  <keyword>life span</keyword>
  <keyword>disease onset</keyword>
  <keyword>grip strength</keyword>
  <keyword>protein expression</keyword>
  <keyword>DNA microarray</keyword>
  <keyword>differential expression</keyword>
  <keyword>Phase 1 clinical trial</keyword>
  <keyword>rare disease</keyword>
  <keyword>common underlying pathogenic mechanisms</keyword>
  <keyword>neurological deficits</keyword>
  <keyword>gene mutation</keyword>
  <keyword>misfolded proteins</keyword>
  <keyword>inadvertent errors</keyword>
  <keyword>modulation of genes</keyword>
  <keyword>master regulator peptide drug</keyword>
  <keyword>ALS related genes</keyword>
  <keyword>mitochondria dysfunction</keyword>
  <keyword>excitotoxicity</keyword>
  <keyword>axonal transport</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>protein aggregation</keyword>
  <keyword>pathogenesis</keyword>
  <keyword>target biomarkers</keyword>
  <keyword>efficacy biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

